Clinical Trial Update: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for zanidatamab in combination with chemotherapy with or without tislelizumab in HER2-positive advanced or metastatic gastric and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanidatamab

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Gastric Neoplasms, Gastroesophageal Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING